Amneal Pharmaceuticals Stock Quote AMRX - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

5.87

Bid

Ask

Volume

0.00 Day's Range 0.00

2.96 52 Week Range 5.95

Market Cap

1.812B

Previous Close

5.87

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

308,651,373

Dividend Yield

PE Ratio

-21.57

Earnings Per Share (EPS)

-0.27

Revenue

2.41B

Net Profit

-83.99M

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inha... Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.amneal.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Amneal Pharmaceuticals Holding Co is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker AMRX. The last closing price for Amneal Pharmaceuticals was $5.87. Over the last year, Amneal Pharmaceuticals shares have traded in a share price range of $ 2.96 to $ 5.95.

Amneal Pharmaceuticals currently has 308,651,373 shares outstanding. The market capitalization of Amneal Pharmaceuticals is $1.81 billion. Amneal Pharmaceuticals has a price to earnings ratio (PE ratio) of -21.57.

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company...

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched...

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO® & FYLNETRA®) ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III Kashiv BioSciences...

Amneal Releases 2023 Environmental, Social and Governance Report

Fourth ESG Report Details Company’s Progress Towards Environmental Sustainability and Contributions Toward Building Healthier Communities as a Leading Provider of Accessible Medicines Amneal...

Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies

The Company’s leading R&D capabilities and robust, expanded manufacturing capacity are helping to address chronic market shortages Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the...

Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California

Significantly expanding access to affordable, life-saving opioid overdose rescue medicine Entered distribution agreement with California; actively engaging with other states and municipalities to...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	2.85	94.3708609272	3.02	5.95	2.96	1260307	4.20237125	CS
156	1.5	34.3249427918	4.37	5.99	1.24	1009095	3.46770438	CS
260	2.35	66.7613636364	3.52	7.445	1.24	1329698	3.9951397	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SILOSilo Pharma Inc	$ 2.18 (103.74%)	137.17M
TKLFYoshitsu Company Ltd	$ 0.5604 (82.99%)	293.09M
NAASNaaS Technology Inc	$ 4.415 (57.68%)	16.97M
VRPXVirpax Pharmaceuticals Inc	$ 1.4493 (35.45%)	11.4M
LCFYLocafy Ltd	$ 4.88 (33.70%)	5.23M
CYNCYNGN Inc	$ 6.85 (-25.38%)	852.79k
AMIXAutonomix Medical Inc	$ 1.08 (-21.74%)	5.61M
NBSTWNewbury Street Acquisition Corporation	$ 0.090295 (-18.43%)	120
AEHLAntelope Enterprise Holdings Ltd	$ 4.23 (-18.18%)	382.51k
ITRMIterum Therapeutics PLC	$ 1.295 (-18.04%)	466.28k
TKLFYoshitsu Company Ltd	$ 0.5604 (82.99%)	293.09M
MAXNMaxeon Solar Technologies Ltd	$ 0.2505 (10.35%)	184.44M
NVDANVIDIA Corporation	$ 126.0199 (-1.88%)	144.85M
SILOSilo Pharma Inc	$ 2.18 (103.74%)	137.17M
SQQQProShares UltraPro Short QQQ	$ 7.54 (1.07%)	98.73M